Ultragenyx is trading 4.5% down today at $24.86 following a broader pullback in the biotechnology sector.
- The move appears driven by risk-off sentiment rather than company-specific news or catalysts reported on July 31, 2026.
- The decline is aligned with the wider sector, as the XBI ETF has fallen more than 3%.
- The stock is currently giving back a portion of the gains seen during the prior day's rebound.